Pharma transactions during the COVID-19 pandemic

How resilient were they?

Whitepaper front cover
whitepaper

Provided by

Sterling logo

FREE DOWNLOAD

With deal volumes in pharma going against forecasts and rising significantly during the pandemic, this paper takes a close look at how deal flow was maintained during such tough working conditions. Of course, new processes played a big role. But so did the attitudes and resilience of those individuals involved who had to adapt to such unfamiliar conditions.

This paper explores the: 

• Use of technology, from zoom to digital signatures 

• Subsequent increased scrutiny on cyber security and business continuity 

• Impact on contract negotiation, speed of decision making and people 

• Post pandemic world and what it could hold for deals in pharma going forward 

. 

Recommended

What does a CISO do?
Careers & training

What does a CISO do?

6 Sep 2021
CTO job description: What does a CTO do?
Business strategy

CTO job description: What does a CTO do?

26 Aug 2021
Renewable energy: What works and what's on the way?
Whitepaper

Renewable energy: What works and what's on the way?

23 Aug 2021
Green deals: The role of sustainability in M&A
Whitepaper

Green deals: The role of sustainability in M&A

23 Aug 2021

Most Popular

Zoom: From pandemic upstart to hybrid work giant
video conferencing

Zoom: From pandemic upstart to hybrid work giant

14 Sep 2021
What are the pros and cons of AI?
machine learning

What are the pros and cons of AI?

8 Sep 2021
Google takes down map showing homes of 111,000 Guntrader customers
data breaches

Google takes down map showing homes of 111,000 Guntrader customers

2 Sep 2021
Intuit plans end-to-end SMB platform after $12 billion Mailchimp acquisition
mergers and acquisitions

Intuit plans end-to-end SMB platform after $12 billion Mailchimp acquisition

14 Sep 2021